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Mast cells are sentinels for infection. Upon exposure to pathogens, they release their stores of proinflam-
matory cytokines, chemokines, and histamine. Mast cells are also important for the control of certain
tick-borne infections. Anaplasma phagocytophilum is an obligate intracellular tick-transmitted bacterium that
infects neutrophils to cause the emerging disease granulocytic anaplasmosis. A. phagocytophilum adhesion to
and infection of neutrophils depend on sialylated and 1,3-fucosylated glycans. We investigated the hypotheses
that A. phagocytophilum invades mast cells and inhibits mast cell activation. We demonstrate that A. phago-
cytophilum binds and/or infects murine bone marrow-derived mast cells (BMMCs), murine peritoneal mast
cells, and human skin-derived mast cells. A. phagocytophilum infection of BMMCs depends on 1,3-fucosylated,
but not sialylated, glycans. A. phagocytophilum binding to and invasion of BMMCs do not elicit proinflamma-
tory cytokine secretion. Moreover, A. phagocytophilum-infected cells are inhibited in the release of tumor
necrosis factor alpha (TNF-), interleukin 6 (IL-6), IL-13, and histamine following stimulation with IgE or
antigen. Thus, A. phagocytophilum mitigates mast cell activation. These findings potentially represent a novel
means by which A. phagocytophilum usurps host defense mechanisms and shed light on the interplay between
mast cells and vector-borne bacterial pathogens.
Mast cells are inflammatory cells strategically located at sites
that are exposed to the external environment such as the skin,
intestines, and airways. Their location, coupled with the pres-
ence of preformed mediators in their cytoplasmic granules,
makes them well suited to be first responders against pathogen
invasion. The significance of mast cells in host defense has
become increasingly recognized in recent years (7, 22). Classic
mast cell degranulation is induced in response to antigen-
specific IgE, which cross-links Fcε receptor I (FcεRI) on the
mast cell surface in the presence of antigen (1, 22). This acti-
vation results in rapid exocytosis of preformed granules con-
taining histamine, proteoglycans, and serine proteases fol-
lowed by synthesis of other mediators, including cytokines and
chemokines (1, 18, 20, 26, 27). Pathogen activation of mast
cells prompts release of preformed and newly synthesized me-
diators that are critical for inflammatory cell recruitment and
resolution of infection (1, 27). For instance, mast cell-derived
tumor necrosis factor alpha (TNF-) and interleukin 6 (IL-6)
are important for bacterial clearance and improved host sur-
vival (6, 19, 21, 35).
Mast cells have been documented at tick feeding sites in the
skin and have been shown to respond to arthropods that are
acquiring blood meals at the dermis (4, 5, 44). Mast cell-
released mediators are implicated in the development of im-
munity to molecules in the saliva of feeding ticks and in im-
parting resistance to tick feeding (24, 25, 40). For instance,
mast cell-deficient mice acquire resistance to feeding ticks only
after being reconstituted with cultured mast cells or bone mar-
row-derived mast cells from wild-type mice. Acquisition of tick
immunity is linked to reduction in pathogen transmission from
infected ticks (14, 43, 45). Furthermore, mast cells play crucial
roles in responding to tick-borne pathogens, as Borrelia burg-
dorferi and Francisella tularensis stimulate mast cell production
of TNF- and IL-4, respectively, each of which limits the
spread of infection (17, 36). The interplay between mast cells
and other tick-borne pathogens is unknown. Since mast cells
are critical for mounting an immune response to tick-derived
antigens during tick feeding and for combating the transmis-
sion of tick-borne infections, it stands to reason that tick-
transmitted pathogens may have evolved strategies for avoid-
ing and/or directly inhibiting mast cell activation.
Anaplasma phagocytophilum is the etiologic agent of human
granulocytic anaplasmosis (HGA), which is a potentially fatal
disease that is transmitted by Ixodes ticks. HGA is the second
most common tick-transmitted infection in the United States
and is also found in Europe and Asia where it is endemic
(38). A. phagocytophilum is an obligate intracellular, vacuole-
adapted bacterium that displays an unusual tropism for neu-
trophils. The bacterium exhibits a biphasic developmental cycle,
transitioning between an adherent and invasive dense-cored
cell (DC) and a noninfectious reticulate cell (RC) that divides
by binary fission (39). A. phagocytophilum infection of neutro-
phils requires sialylated and 1,3-fucosylated receptors (3, 9,
12, 47). Whether the pathogen infects host cell types other
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than neutrophils upon tick inoculation is unknown. A. phago-
cytophilum infects myeloid cell lines, such as HL-60, as well as
endothelial, megakaryocytic, and tick embryonic cell lines (10,
11, 46).
Given that mast cells are present at the ixodid tick bite site
and because A. phagocytophilum is able to infect a variety of
host cell types in addition to neutrophils in vitro (10, 11, 28), we
investigated whether the bacterium is capable of infecting mast
cells. Our findings reveal that A. phagocytophilum binds to and
invades murine bone marrow-derived mast cells (BMMCs) and
human skin-derived mast cells. A. phagocytophilum binding to
and entry into mast cells involve 1,3-fucosylated, but not
sialylated, receptors. A. phagocytophilum infection of mast cells
does not elicit a cytokine response or degranulation. More-
over, it suppresses IgE- or antigen (Ag)-mediated activation of
cytokine, chemokine, and histamine release. Our findings re-
veal a novel means by which A. phagocytophilum modulates the
host cell response.
MATERIALS AND METHODS
Cultivation of uninfected and A. phagocytophilum-infected myeloid cell lines.
The human promyelocytic cell line HL-60 and HL-60 cells infected with A.
phagocytophilum (NCH-1 strain) were cultivated in Iscove’s modified Dulbecco’s
Eagle medium (IMDM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS) (IMDM-10) as described previously (2, 8). A. phagocytophi-
lum NCH-1A2 was cultured in sialyl transferase- and 1,3-fucosyltransferase-
defective HL-60 A2 cells as described previously (9, 32).
Mouse and human mast cell cultures. Murine bone marrow-derived mast cells
(BMMCs) were harvested from the tibias and fibulas of C57BL/6, C57BL/6 
129, and Fuc-TIV//Fuc-TVII/ mice [Fuc-TIV stands for (1,3)-fucosyl-
transferase IV] (13). BMMCs were harvested from both C57BL/6 and C57BL/
6  129 mice to assess whether BMMCs from different genetic backgrounds are
susceptible to A. phagocytophilum infection. BMMCs were cultured in complete
RPMI 1640 medium (cRPMI; Invitrogen, Carlsbad, CA) containing 10% FBS, 1
mM sodium pyruvate, 2 mM L-glutamine, and 1 mM HEPES (Biofluids, Rock-
ville, MD) supplemented with IL-3-containing supernatant from WEHI-3 cells
and stem cell factor (SCF)-containing supernatant from BHK-MHL cells. The
mast cell phenotype was confirmed by flow cytometric staining with fluorescein
isothiocyanate (FITC)-conjugated anti-c-Kit antibody (BD Biosciences, San
Jose, CA) and phycoerythrin (PE)-conjugated FcεRI (eBiosciences, San Diego,
CA), analyzed with a FACSCalibur (BD Biosciences, San Jose, CA). At the time
of use, BMMC cultures were more than 90% mast cells. Mouse peritoneal mast
cells were obtained by lavage of the peritoneal cavity with 6 ml of cRPMI. Fluid
was recovered with a Pasteur pipette after vigorous massage of the peritoneum
to loosen peritoneal cells. Surgical skin samples were obtained from the Coop-
erative Human Tissue Network of the National Cancer Institute or from the
National Disease Research Interchange. Skin mast cells (Sk-MCs) were pre-
pared as previously described (48) and were 100% mast cells, as determined by
staining with toluidine blue. All protocols involving mouse and human tissues
were approved by the Virginia Commonwealth University (VCU) Institutional
Animal Care and Use Committee and the human studies Internal Review Board,
respectively.
Assessment of A. phagocytophilum binding and infection. Host cells were in-
cubated with host cell-free Anaplasma organisms that had been obtained from 4
times the number of infected HL-60 cells as those to be infected. The amounts
of host cell-free NCH-1 and NCH-1A2 organisms were normalized according to
spectrophotometric measurements at an optical density at 600 nm (OD600).
After 40 min, unbound bacteria were removed by washing the cells with phos-
phate-buffered saline (PBS). A. phagocytophilum organisms that were observed
adhering to the host cell surface at 40 min were classified as bound bacteria. Host
cells harboring intravacuolar colonies of A. phagocytophilum in the cytoplasm
(morulae) were classified as infected (39). The numbers of bound A. phagocyto-
philum per cell and morulae per cell were recorded using indirect immunofluo-
rescence microscopy at 40 min and at various postinfection time points, respec-
tively, as described previously (2). Primary antibodies used to assess infection
were rabbit polyclonal antiserum and mouse monoclonal antibody (MAb) 20B4
(29) (a gift from J. Stephen Dumler, Johns Hopkins University, Baltimore, MD)
targeting the A. phagocytophilum major surface protein Msp2 (P44). In some
cases, host cells were treated with sialidases or mock treated with Hanks buffered
salt solution (HBSS) and 1% FBS prior to incubation with A. phagocytophilum
(3). Bacterial binding to and infection of BMMCs were also analyzed by trans-
mission electron microscopy as described previously (39). For assessment of
bacterial binding to peritoneal mast cells ex vivo, host cell-free NCH-1 organisms
were fluoresceinated using CellTracker green (Invitrogen) as described previ-
ously (3). CellTracker green-labeled A. phagocytophilum organisms were incu-
bated with 106 peritoneal cells for 30 min at room temperature. Unbound
bacteria were removed by centrifugation at 300  g for 5 min, and A. phagocy-
tophilum binding to mast cells was detected by flow cytometry using PE-conju-
gated anti-c-Kit antibody for mast cell detection.
Measurement of cytokine and/or histamine release. To determine whether A.
phagocytophilum infection elicits cytokine release from mast cells, BMMCs were
incubated with host cell-free A. phagocytophilum organisms or Escherichia coli or
were mock infected for 3, 6, or 12 h at 37°C. The mock-infected control sample
that was added to BMMCs corresponds to the minute amount of contaminating
HL-60 cellular debris that remains associated with each sample of A. phagocy-
tophilum organisms following release from HL-60 cells by mechanical lysis and
the washing steps. To generate the mock-infected sample, the same number of
uninfected HL-60 cells as infected cells from which A. phagocytophilum bacteria
were obtained was processed in parallel with infected HL-60 cells. The barely
discernible pellet of HL-60 cellular debris that remained after the washing steps
was resuspended in medium and added to BMMCs in the exact same manner as
A. phagocytophilum organisms that had been obtained from infected HL-60 cells.
The amounts of E. coli and host cell-free A. phagocytophilum organisms were
normalized according to spectrophotometric measurements at OD600. Superna-
tants from BMMCs that had been incubated with A. phagocytophilum, E. coli, or
mock-infected control were collected at each time point and measured for levels
of tumor necrosis factor alpha (TNF-), interleukin 1 (IL-1), IL-4, IL-5, IL-6,
IL-10, IL-13, IL-17, granulocyte-macrophage colony-stimulating factor (GM-
CSF), monocyte chemotactic peptide 1 (MCP-1), macrophage inflammatory
protein 1 (MIP-1), and MIP-1 using the Bio-Plex 200 system (Bio-Rad,
Hercules, CA). To determine whether A. phagocytophilum infection inhibits
IgE-induced histamine and/or cytokine release in an infection load-dependent
manner, BMMCs were incubated with A. phagocytophilum NCH-1A2 organisms
or various concentrations of NCH-1 organisms for 3 h, after which unbound
bacteria were removed by washing with PBS. The host cells were sensitized with
0.5 g/ml mouse anti-dinitrophenol (anti-DNP) IgE (BD PharMingen, San Di-
ego, CA) overnight at 37°C in a 5% CO2 atmosphere, washed, and resuspended
at a concentration of 106 cells/ml. The cells were then activated with 50 ng/ml
DNP-human serum albumin (HSA) at 37°C for 1 h or 24 h for subsequent
analysis of histamine or cytokine release, respectively. Cells incubated in the
absence of DNP-HSA served as negative controls. Histamine levels in the su-
pernatant were measured using a histamine enzyme-linked immunosorbent assay
(ELISA) kit (Neogen, Lansing, MI). Supernatant levels of TNF-, IL-6, and
IL-13 were measured using OptEIA ELISA kits (Peprotech, Rocky Hill, NJ).
Statistical analyses. Statistical analyses were performed using the Prism 4.0
software package (Graphpad; San Diego, CA). If one-way analysis of variance
(ANOVA) indicated a group difference (  0.05), then Dunnett’s posthoc test
was used to test for a significant difference among groups. In some instances, the
Student t test was used to assess statistical significance. Statistical significance was
set at   0.05.
RESULTS
A. phagocytophilum binds, invades, and replicates within
mast cells. To investigate the ability of A. phagocytophilum to
bind to mast cells, host cell-free A. phagocytophilum organisms
(NCH-1 strain) were incubated with bone marrow-derived
mast cells (BMMCs) for 40 min. After removal of unbound
bacteria, host cells were assessed by transmission electron mi-
croscopy. Dense-cored cell (DC) organisms were observed ad-
hering to the host cell surface, and some were in the process of
being enveloped by filopodia (Fig. 1A). Immunofluorescence
microscopic analysis further confirmed the susceptibility of
BMMCs to NCH-1 binding and entry (Fig. 1B and C). The
percentages of BMMCs from C57BL/6 and C57BL/6  129
mice with bound NCH-1 organisms were comparable, as were
the mean number of bound bacteria per cell (data not shown).
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The percentage of infected BMMCs and the mean number of
bacteria bound to BMMCs were significantly lower than to the
human promyelocytic cell line HL-60 (Fig. 1B and C). To
extend our studies ex vivo using mature tissue resident mast
cells, CellTracker green-labeled NCH-1 organisms were incu-
bated with mast cells obtained from the peritoneal cavities of
mice. Fluoresceinated bacterial binding to c-Kit-positive mast
cells was assessed by flow cytometry. Supernatant from Cell-
Tracker green-labeled NCH-1 was incubated with peritoneal
mast cells as a background control. A. phagocytophilum bound
efficiently to peritoneal mast cells, as the mean fluorescence
intensities of peritoneal mast cells incubated with NCH-1 and
supernatant control were 25.9 and 10.8, respectively (Fig. 1D).
We next assessed whether NCH-1 replicates within mast
cells. BMMCs that had been incubated with A. phagocytophi-
lum were examined by electron microscopy for morulae at 24 h
postinfection. Detection of multiple intravacuolar reticulate
cell (RC) organisms within individual vacuoles indicated that
the DC-to-RC transition and bacterial replication had oc-
curred (Fig. 2A). As revealed by immunofluorescence micros-
copy, NCH-1 infection of BMMCs is less productive than in-
fection of HL-60 cells. Whereas 40%  9.8% of HL-60 cells
was infected with 4.6  0.7 morulae per infected cell at 24 h,
only 14.3%  3.2% of BMMCs was infected with 1.5  0.1
morulae per infected cell (Fig. 2B and C). By 48 h, NCH-1
infection of BMMCs had declined, as 6.5%  2.2% BMMCs
contained bacterial inclusions with 1.6  0.1 morulae per cell
(Fig. 2D and E). The degrees of A. phagocytophilum binding to
and entry of BMMCs derived from C57BL/6 and C57BL/6 
129 mice were comparable (data not shown). In contrast, the
percentage of NCH-1-infected HL60 cells and the number of
morulae per infected cell had risen to 70  6.0 and 4.8  0.7,
respectively, by 48 h.
A. phagocytophilum NCH-1 binding to BMMCs is sialic acid
independent. To determine whether sialic acid residues are
important for A. phagocytophilum adhesion to BMMCs, we
incubated NCH-1 organisms with BMMCs that had been
treated with sialidases and determined the percentage of host
cells with bound bacteria and the mean number of bound
bacteria per cell. Consistent with earlier observations (3, 9, 12,
33, 47), sialidase treatment of control HL-60 cells significantly
diminished NCH-1 binding (Fig. 3A and B). In contrast, siali-
dase treatment of BMMCs had no effect on NCH-1 binding.
A. phagocytophilum bound equally well to sialidase-treated
BMMCs derived from C57BL/6 and C57BL/6  129 mice
(data not shown).
FIG. 1. A. phagocytophilum adheres to bone marrow-derived mast
cells (BMMCs). (A) Host cell-free NCH-1 organisms were incubated
with BMMCs. After 40 min, unbound bacteria were removed, and
BMMCs were analyzed by transmission electron microscopy. NCH-1
dense-cored cell (DC) organisms were observed binding to the surface
of and being enveloped by BMMCs. The black arrow denotes a DC
organism simultaneously interacting with the surfaces of two BMMCs.
The black arrowheads denote DC organisms that have been internal-
ized into a vacuole or are in the process of being engulfed. Note the
presence of intact cytoplasmic granules in the BMMCs. Bar, 1 m. (B
and C) Binding of NCH-1 DC organisms to HL-60 cells or BMMCs
was assessed by indirect immunofluorescence microscopy. Panels B
and C show the percentages of HL-60 cells or BMMCs with bound
NCH-1 bacteria and the mean numbers plus standard deviations (SDs)
(error bars) of bound NCH-1 organisms per cell, respectively. Data
shown are the mean of three independent experiments, each of which
was performed using mast cell populations derived from C57BL/6 and
C57BL/6  129 mice. Ap, A. phagocytophilum. *, P  0.05; **, P 
0.005. (D) Binding of NCH-1 to freshly isolated peritoneal mast cells.
CellTracker green-labeled NCH-1 organisms were incubated with mu-
rine peritoneal cells. Bacterial binding was directly correlated to Cell-
Tracker green fluorescence using flow cytometry. Peritoneal mast cells
incubated with supernatant from CellTracker green-labeled NCH-1
organisms served as a control for background fluorescence. Results
shown are representative of two independent experiments.
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A. phagocytophilum NCH-1 is dependent on 1,3-fucosylated
glycans for adhesion, while NCH-1A2, which productively in-
fects BMMCs and human skin-derived mast cells, is consid-
erably less dependent. To investigate the importance of 1,3-
fucosylated receptors to A. phagocytophilum binding to murine
mast cells, host cell-free NCH-1 organisms were incubated
with Fuc-TIV//Fuc-TVII/ BMMCs. In contrast to wild-
type BMMCs, NCH-1 binding to Fuc-TIV//Fuc-TVII/
BMMCs was reduced 2.4-fold (Fig. 3C and D). Despite the
overall critical importance of sialylated and 1,3-fucosylated
glycans to A. phagocytophilum adherence, subpopulations of A.
phagocytophilum organisms that do not depend on these de-
terminants for adhesion exist (31–33). Such organisms can be
selected for by repeated passage in the clonal cell line HL-60
A2, which is devoid of sialylated and 1,3-fucosylated glycans
(9, 32, 33). NCH-1A2 is an enriched subpopulation that was
obtained by cultivating NCH-1 in HL-60 A2 cells (32). NCH-
1A2 bacteria bound to a percentage of Fuc-TIV//Fuc-
TVII/ BMMCs that was comparable to that of wild-type
BMMCs and bound to considerably higher percentages of both
Fuc-TIV//Fuc-TVII/ and wild-type BMMCs than NCH-1
organisms (Fig. 3C and D). Significantly fewer NCH-1A2 bac-
teria bound to Fuc-TIV//Fuc-TVII/ BMMCs than to
wild-type BMMCs (Fig. 3D). However, greater numbers of
NCH-1A2 organisms bound to both Fuc-TIV//Fuc-TVII/
and wild-type BMMCs than NCH-1 organisms (Fig. 3D).
We next sought to directly compare NCH-1A2 binding and
infection kinetics of BMMCs with those of NCH-1. BMMCs
were incubated with normalized amounts of either NCH-1 or
NCH-1A2 organisms, and host cells were monitored for bac-
terial adherence and morula development. NCH-1A2 organ-
isms bound to a slightly greater percentage of BMMCs with a
significantly greater number of bacteria binding per BMMC
than NCH-1 (Fig. 4A and B). The efficacy of NCH-1A2 infec-
tion of BMMCs far exceeded that observed for NCH-1, as
significantly higher percentages of BMMCs with NCH-1A2
morulae were observed at both 24 and 48 h postinfection (Fig.
4C). Moreover, by 48 h postinfection, the number of NCH1-A2
morulae exceeded the number of NCH-1 morulae by approx-
imately 5-fold (Fig. 4D). We next extended our analyses to
human mast cells. NCH-1 and NCH-1A2 binding and infection
kinetics of human skin-derived mast cells exhibit trends similar
to those observed for murine BMMCs (Fig. 5).
A. phagocytophilum infection of mast cells does not elicit the
release of cytokines or chemokines. After observing that A.
phagocytophilum adheres to and infects mast cells, we investi-
FIG. 2. A. phagocytophilum invades and replicates within bone
marrow-derived mast cells. Host cell-free NCH-1 organisms were in-
cubated with BMMCs for 40 min, after which unbound bacteria were
removed. (A) At 24 h postinfection, host cells were examined by
transmission electron microscopy. A representative BMMC harboring
two NCH-1 RC bacteria within a vacuole is presented. Note the pres-
ence of cytoplasmic granules throughout the BMMC. Additional ex-
periments were performed in which A. phagocytophilum infection was
assessed using indirect immunofluorescence microscopy. A. phagocyto-
philum infection was measured by the presence of morulae in the mast
cells at 24 and 48 h. Panels B and C present the percentages of HL-60 cells
or BMMCs with morulae at 24 h and 48 h, respectively. Panels D and E
present the mean numbers plus SDs of morulae per infected HL-60 cell
or BMMC at 24 h and 48 h, respectively. Data are means of three
experiments. *, P  0.05; **, P  0.005; ***, P  0.001.
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gated whether these events stimulate release of cytokines and
chemokines that are associated with the mast cell antibacterial
response. BMMCs were infected with NCH-1 or NCH-1A2
organisms, and the supernatant was assessed over a 24-h time
course for a panel of 12 cytokines and chemokines that are
typically released by mast cells in response to exposure to
pathogens. Aliquots of BMMCs were confirmed for bound
and/or internalized A. phagocytophilum organisms by indirect
immunofluorescence microscopy (data not shown). As a posi-
tive control, BMMCs were incubated with equivalent amounts
of E. coli. Of the 12 cytokines/chemokines measured, 5 (IL-1,
IL-6, IL-13, MIP-1, and MIP-1) were detected in the super-
natants (Fig. 6). Of note, there were no detectable levels of
TNF-, IL-4, and IL-5 released in response to A. phagocyto-
philum infection. Moreover, neither NCH-1 nor NCH-1A2
elicited a significant increase in the level of IL-1, IL-6, IL-13,
MIP-1, or MIP-1 compared to mock-infected cells (Fig. 6).
In contrast, exposure to E. coli stimulated higher levels of all
chemokines and cytokines examined compared to mock-in-
fected cells. Incubating BMMCs with fivefold-less E. coli than
A. phagocytophilum organisms yielded similar results (data not
shown).
A. phagocytophilum infection inhibits IgE-mediated mast cell
cytokine and histamine release in a bacterial dose-dependent
manner. After observing that A. phagocytophilum infection
does not elicit the release of inflammatory cytokines or chemo-
kines, we investigated whether infection alters IgE/Ag-medi-
ated mast cell activation. NCH-1, NCH-1A2, or mock-infected
IgE-sensitized BMMCs were activated with IgE plus dinitro-
phenol (DNP)-human serum albumin (HSA) for 24 h, after
which the supernatants were assessed for the presence of
TNF-, IL-6, and IL-13, which are classical proinflammatory
cytokines released by mast cells that promote inflammation. As
expected, NCH-1A2 achieved a considerably higher bacterial
burden than NCH-1 did (Fig. 7). Mock-infected mast cells
released large amounts of TNF-, IL-6, and IL-13 upon acti-
vation (Fig. 7A to C). NCH-1-infected BMMCs released
slightly, but not statistically significantly, lower levels of cyto-
kines than mock-infected cells. Cytokine production in NCH-
1A2-infected cells was significantly reduced compared to
mock-infected cells. Mast cell viability and cell numbers were
unaffected by NCH-1 or NCH-1A2 infection (data not shown).
Surface expression of c-Kit and FcεRI were comparable in
mock-infected and A. phagocytophilum-infected cells, as deter-
mined by flow cytometry (data not shown), which suggests that
the disruption of cytokine/chemokine release in A. phagocyto-
philum-infected mast cells is not due to altered expression of
these receptors.
Since the BMMCs infected with NCH-1A2 had a signifi-
cantly higher bacterial load than those infected with NCH-1,
we reasoned that the observed inhibition of mast cell cytokine
release is A. phagocytophilum dose dependent. To test our
hypothesis, we infected BMMCs with increasing numbers of
NCH-1 organisms to approximate the bacterial load achieved
by NCH-1A2 and subsequently activated the cells with IgE/
DNP-HSA for 24 h. IgE/Ag-stimulated cytokine release from
BMMC populations of which 21.0%  5.0%, but not 15.5% 
0.5% of cells were infected was significantly inhibited com-
pared to mock-infected cells (Fig. 7D to F). We next investi-
gated whether A. phagocytophilum infection also alters the
FIG. 3. A. phagocytophilum (Ap) NCH-1 binding to BMMCs does
not depend on sialic acid, but it does depend on 1,3-fucose. HL-60
cells and BMMCs were mock treated or treated with sialidase prior to
incubation with host cell-free NCH-1 organisms. Unbound bacteria
were removed after 40 min. Panels A and B present the percentages of
HL-60 or BMMCs with bound NCH-1 organisms and the mean num-
bers plus SDs of bound NCH-1 bacteria per cell, respectively, as
determined by indirect immunofluorescence microscopy. (C and D)
Binding of NCH-1 and NCH-1A2 to wild-type and FucTIV//
FucTVII/ BMMCs was analyzed by indirect immunofluorescence
microscopy. Panels C and D present the percentages of BMMCs with
bound A. phagocytophilum bacteria and the mean numbers plus SDs of
bound A. phagocytophilum organisms per cell, respectively. Data are
representative of 2 independent experiments. *, P  0.05; **, P 
0.005; ***, P  0.001.
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early phase of mast cell activation by assessing bacterial load
and histamine release. Culture supernatants of NCH-1-, NCH-
1A2-, and mock-infected BMMCs activated with IgE/DNP-
HSA for 1 h were tested for the presence of histamine. Only
6.8%  1.9% of BMMCs were infected with NCH-1 with 1.4 
0.2 morulae per infected cell at the time at which histamine
release was assessed (Fig. 8). This low infection load did not
yield a detectable inhibition of IgE-stimulated histamine re-
FIG. 4. A. phagocytophilum NCH-1A2 binds and invades murine BMMCs more efficiently than NCH-1. Host cell-free NCH-1 and NCH-1A2
organisms were incubated with murine BMMCs for 40 min. (A and B) Following removal of unbound bacteria, mast cells were examined for A.
phagocytophilum (Ap) binding by indirect immunofluorescence microscopy. (C and D) The infections were allowed to proceed for 48 h, during which
aliquots were assayed for bacterial load at 24 and 48 h. (A) Percentages of BMMC with bound NCH-1 or NCH-1A2 organisms. (B) Mean numbers plus
SDs of bound NCH-1 or NCH-1A2 organisms per BMMC. (C) Percentages of BMMC with morulae. (D) Mean numbers plus SDs of morulae per
infected BMMC. Results presented are the mean values plus SDs of three independent experiments. *, P  0.05; **, P  0.005; ***, P  0.001.
FIG. 5. A. phagocytophilum NCH-1A2 binds and invades human skin-derived mast cells more efficiently than NCH-1 does. Host cell-free
NCH-1 and NCH-1A2 organisms were incubated with human skin-derived mast cells for 40 min. (A and B) Following removal of unbound bacteria,
mast cells were examined for A. phagocytophilum (Ap) binding by indirect immunofluorescence microscopy. (C and D) The infections were allowed
to proceed for 48 h, during which aliquots were assayed for bacterial load at 24 and 48 h. (A) Percentages of skin-derived mast cells with bound
NCH-1 or NCH-1A2 organisms. (B) Mean numbers plus SDs of bound NCH-1 or NCH-1A2 organisms per skin-derived mast cell. (C) Percentages
of skin-derived mast cells with morulae. (D) Mean numbers plus SDs of morulae per infected skin-derived mast cell. Results presented are the
mean values  SDs of three independent experiments. *, P  0.05.
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lease, as histamine levels elicited from mock-infected and
NCH-1-infected BMMCs were comparable. In contrast,
29.0%  2.5% of BMMCs were infected with NCH-1A2 with
2.9  0.5 morulae per infected cell. The higher NCH-1A2
burden translated to a significant decrease in IgE-stimulated
histamine production, as there was a 34% reduction in hista-
mine levels compared to histamine levels released by mock-
infected cells.
DISCUSSION
Mast cells are crucial for initiating innate and adaptive im-
mune responses that are critical for preventing bacterial dis-
semination and clearing bacterial infections (6, 15, 16, 34, 37).
Mast cells’ proximity to the vasculature and the rapid kinetics
by which their mediators are released upon encounter with
pathogens distinguishes them from other immune cells (1, 23).
Given their abundant expression in the skin and their ability to
recruit effector cells (41, 42), mast cells are likely critical in
mounting immune resistance to arthropod vector-borne dis-
eases. This study provides the first evidence that A. phagocy-
tophilum infects mast cells. DC organisms adhere to BMMCs
and are internalized by murine BMMCs from different genetic
backgrounds. The bacterium also binds fully differentiated mu-
rine peritoneal mast cells and human skin-derived mast cells.
Sialic acid is dispensable for A. phagocytophilum binding to
murine BMMCs, while 1,3-fucosylation is critical. The ability
of A. phagocytophilum to infect human neutrophils and HL-60
cells is linked to P-selectin glycoprotein ligand 1 (PSGL-1) and
other sialylated and 1,3-fucosylated receptors (3, 9, 12, 47).
Sialylated glycans are important and 1,3-fucosylated glycans
are essential, while PSGL-1 is not involved in A. phagocytophi-
lum infection of murine neutrophils (3, 47). 1,3-Fucose is
important for the bacterium to colonize its ixodid tick vector
(30). Thus, while A. phagocytophilum differentially utilizes
PSGL-1 and sialic acid to infect different cell types, its target-
ing of 1,3-fucosylated receptors is conserved among suscep-
tible host cells.
The percentage of BMMCs with NCH-1 morulae and bac-
terial load per infected BMMC declined over the course of
infection, whereas infection of control HL-60 cells increased
throughout the time course. This is likely because NCH-1 does
not bind as efficiently to BMMCs as to HL-60 cells, perhaps
because the 1,3-fucosylated receptor is in relatively low abun-
dance on the BMMC surface. Support for this premise comes
from our observations that significantly fewer bacteria bound
to BMMCs than to HL-60 cells, which translated to signifi-
cantly less morulae per infected BMMC than per infected
HL-60 cell. This, in turn, results in significantly fewer infec-
tious DC progeny being released from BMMCs than HL-60
cells following each round of NCH-1 RC to DC conversion.
Over the course of the experiment, BMMC division outpaces
the release of DC, which dilutes the infection. In contrast, the
FIG. 6. Mast cells do not secrete cytokines or chemokines follow-
ing A. phagocytophilum infection. BMMCs were incubated for 3, 6, or
24 h with NCH-1 or NCH-1A2 bacteria, mock control, or E. coli.
Cell-free supernatants were collected and assessed for 12 cytokines
and chemokines that are typically released from mast cells upon stim-
ulation using the Bio-Plex 200 system assay, as described in Materials
and Methods. Of these12 cytokines and chemokines, only IL-1 (A),
IL-6 (B), IL-13 (C), MIP-1 (D), and MIP-1 (E) were detectable.
Results are means plus SDs of triplicate determinations. *, P  0.05;
**, P  0.005; ***, P  0.001.
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amount of infectious DC released from HL-60 cells increases
by approximately 5-fold following each round of RC-to-DC
conversion, which yields a higher bacterial load as the time
course progresses. Further support for our argument comes
from the fact that NCH-1A2 organisms, which do not depend
on 1,3-fucosylated receptors (32), were able to productively
infect BMMCs, as the percentage of BMMCs with NCH-1A2
morulae and NCH-1A2 load per infected BMMC increased
throughout the time course.
Since mast cells are critical for mounting an immune re-
sponse to tick feeding and inhibiting tick transmission of
pathogens (14, 24, 25, 40, 43, 45), we rationalized that A.
phagocytophilum may have evolved strategies for avoiding
and/or inhibiting mast cell activation. Consistent with our hy-
pothesis, we observed that A. phagocytophilum-infected BMMCs
failed to produce cytokines or chemokines. TNF-, which re-
cruits inflammatory cells to sites of bacterial infection (1, 21),
was undetectable in the supernatants of infected cells. This is
FIG. 7. A. phagocytophilum inhibits IgE-mediated cytokine release from bone marrow-derived mast cells. (A to C) NCH-1-, NCH-1A2-, or
mock-infected BMMCs were sensitized with IgE overnight and subsequently activated with dinitrophenol (DNP)-human serum albumin (HSA)
for 24 h. Duplicate samples that were not primed with IgE served as unstimulated (unstim) controls. Supernatant levels of TNF- (A), IL-6 (B),
and IL-13 (C) were measured by ELISAs. (D to F) To determine whether a greater degree of NCH-1 infection than that achieved in panels A
to C is necessary for detecting a statistically significant decline in IgE-mediated release of cytokines, BMMCs were infected with increasing amounts
of NCH-1 organisms followed by IgE priming, incubation with DNP-HSA, and assessment of TNF- (D), IL-6 (E), and IL-13 (F) supernatant
levels by ELISAs. Mock infection controls were performed for each dosage of NCH-1 organisms. Statistical significance in panels D to F was
determined by comparing the cytokine levels released from NCH-1-infected BMMCs and their corresponding mock-infected controls. Please note
that the overall increases in cytokine levels in panels D to F are due to the fact that considerably more BMMCs were assayed in this set of
experiments than in the experiments presented in panels A to C. The bacterial burdens for panels A to C and panels D to F are listed below panels
C and F, respectively. Data are representative of 3 individual mast cell populations that were assayed in triplicate. *, P  0.05; **, P  0.005; ***,
P  0.001.
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supported by our electron micrographs, which revealed that
mast cells having bound or internalized A. phagocytophilum
organisms do not degranulate. NCH-1- and NCH-1A2-in-
fected BMMCs were significantly inhibited in their abilities to
release TNF-, IL-6, and IL-13 upon IgE stimulation. The fact
that this phenomenon could be detected when only 21 to 30%
of BMMCs were infected suggests that A. phagocytophilum
pronouncedly blocks IgE-mediated mast cell cytokine release.
Exposure to E. coli elicited an inflammatory response, which
ruled out the possibility of an inherent defect in chemokine
and cytokine release from BMMCs. NCH-1A2, but not
NCH-1, inhibited IgE-prompted histamine release. We pre-
sume that this differential result is due to the fact that nearly
one-third of BMMCs had detectable NCH-1A2 infection at the
time of assay, whereas only 6.8%  1.9% of BMMCs were
infected with NCH-1. These data demonstrate the potential of
A. phagocytophilum to not only invade mast cells in a manner
that does not elicit cytokine production but to also actively
inhibit IgE-mediated mast cell activation.
Our findings present the first description of direct interac-
tion between A. phagocytophilum and mast cells and under-
score the proinflammatory inhibitory potential of this patho-
gen. Moreover, our data promote the hypothesis that A.
phagocytophilum would be able to infect mast cells present at
the tick bite site. A complete A. phagocytophilum transmission
cycle in the reservoir mammalian host requires a minimum of
two tick feedings. The first blood meal results in tick acquisi-
tion of the bacterium, while the second transmits the pathogen
to a subsequent reservoir host. In the first blood meal, the host
could conceivably be immunologically naïve and thus have not
mounted resistance to tick feeding, which would allow for
prolonged tick feeding required for transmission. However,
there would be expected to be some level of resistance for the
second feeding, which would be at least partially mast cell
dependent. A. phagocytophilum infection of dermal mast cells
could dampen this resistance to minimize tick rejection and
promote successful transmission feeding, a phenomenon that
would benefit both vector and pathogen. The findings of the
current study set the stage for assessing whether A. phagocy-
tophilum infects mast cells in the dermis and whether such an
infection translates to biologically relevant inhibition of mast
cell-mediated resistance.
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